98%
921
2 minutes
20
Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that certain of the Transwell cell invasion assay data shown in Fig. 2B on p. 42 and the immunofluorescence data shown in Fig. 4D on p. 44 were strikingly similar to data appearing in other articles written by different authors at different research institutes that were submitted to different journals at around the same time. Moreover, a further investigation of this paper undertaken by the Editorial Office identified a large number of overlapping data panels comparing the Transwell cell migration and invasion assay data and the scratch‑wound assay data both within and between Figs. 2 and 3, where data which were intended to have shown the results from differently performed experiments had apparently been derived from the same original source, including an overlapping section of data within the 'MEG3+mimic' panel in Fig. 3G that would be difficult to attribute to pure chance. Owing to the fact that the contentious data in the above article had already been submitted for publication at around the same time as its submission to , and given an overall lack of confidence in the presented data, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 40: 39‑48, 2018; DOI: 10.3892/or.2018.6424].
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11358672 | PMC |
http://dx.doi.org/10.3892/or.2024.8799 | DOI Listing |
Biom J
October 2025
Novella Clinical Full Service, IQVIA, Melbourne, Australia.
Phase I dose escalation trials in oncology generally aim to find the maximum tolerated dose. However, with the advent of molecular-targeted therapies and antibody drug conjugates, dose-limiting toxicities are less frequently observed, giving rise to the concept of optimal biological dose (OBD), which considers both efficacy and toxicity. The estimand framework presented in the addendum of the ICH E9(R1) guidelines strengthens the dialogue between different stakeholders by bringing in greater clarity in the clinical trial objectives and by providing alignment between the targeted estimand under consideration and the statistical analysis methods.
View Article and Find Full Text PDFJ Orthop Res
September 2025
Institute of Orthopaedic Research and Biomechanics, University Medical Center Ulm, Ulm, Germany.
Osteoporotic hip fractures are a considerable cause of pain and disability particularly among the elderly. Osteoporosis causes loss of bone stability, which in turn leads to an increased risk of fractures especially in metaphyseal bone. Moreover, the body's capacity for healing is diminished, resulting in prolonged recovery times following these fractures.
View Article and Find Full Text PDFBackground: This retrospective analysis is a derivative cohort study based on a prior retrospective investigation by this author group.
Objective: To assess the effect of the number of cellular and/or tissue-based product (CTP) applications on healing outcomes and wound area reduction (WAR) rates in patients with chronic wounds of multiple etiologies.
Methods: Data from a multicenter private wound care practice electronic health record database were analyzed for Medicare patients receiving CTPs from January 2018 through December 2023.
Wounds
August 2025
Department of Nursing, Federal University of Ceará, Ceará, Brazil.
Background: To estimate the prevalence of biofilms in chronic wounds.
Methods: The authors performed a systematic review of prevalence studies and meta-analysis, structured according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. Articles were searched in Scopus (Elsevier), Web of Science (Clarivate), MEDLINE/PubMed (National Institutes of Health), and Embase (Elsevier) databases.
Wounds
August 2025
Department of Nursing, Federal University of Ceará, Ceará, Brazil.
Background: Diabetic foot ulcers (DFUs) are a major clinical challenge, particularly among patients with refractory ulcers, that often lead to severe complications such as infection, amputation, and high mortality. Innovations supported by strong clinical evidence have the potential to improve healing outcomes, enhance quality of life, and reduce the economic burden on individuals and health care systems.
Objective: To describe the design of the concurrent optical and magnetic stimulation (COMS) therapy Investigational Device Exemption (IDE) study for refractory DFUs (MAVERICKS) trial.